EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The prognostic value of neutrophil-to-lymphocyte ratio in nasopharyngeal cancer

Mustafa Kandaz, Atalay Balsak, Hatice Bengü Çobanoğlu

Northwestern Medical Journal · 31.01.2025 · 5 (1) · 16-24

DOI: 10.54307/nwmj.2025.77 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Northwestern Medical Journal, online erschienen am 31.01.2025. Verfasst von Mustafa Kandaz und 2 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The prognostic value of the neutrophil-to-lymphocyte ratio (NLR) for nasopharyngeal carcinoma (NPC) continues to be debated. This study was conducted to enhance the accuracy of its prognostic value through a single-centre analysis.

Methods

Ninety-seven patients with NPC who received adjuvant radiotherapy between 1998 and 2022 were analyzed retrospectively.

Results

The study included a total of 97 patients who were treated for NPC and had available data. In 54 (56%) patients the NLR was ≤3 and in 43 (44%) the NLR was >3. The mean age of the patients was 49.64±14.51 (range: 12-82) years. Four patients were ≤18 years old and 93 patients were >19 years old. Sixty-three (65%) patients were male, 34 (35%) patients were female. For stage I patients, NLR was ≤3 in 2 (2%) and >3 in 2 (2%) patients. For stage II patients, NLR was ≤3 in 10 (11%) and >3 in 8 (8%) patients. For stage III patients, NLR was ≤3 in 29 (30%) and >3 in 25 (26%) patients. For stage IVA patients, NLR was ≤3 in 12 (12%) and >3 in 8 (8%) patients. For stage IVB patients, NLR was >3 in 1 (1%). The follow-up period was 79.4±72.1 (2-279) months. In all patients, mean overall survival (OS) was 159.37±13.66 (132.97-185.76) months, median 205±31.11 (144-265.99) months, The 1-, 2- , 3- and 5-year survival rates were 87.3%, 81.5%, 74.3%, and 65.3%, respectively. In general, 54 (56%) of the patients had NLR ≤3, while 43 (44%) had NLR >3. Mean survival times were 169.72±14.2 (95%CI 141.86-197.56) and 133.88±18.95 (95%CI 96.72-171.03) months for NLR ≤3 and NLR >3 patients, respectively. Median survival time was 223 months for NLR ≤3 patients, whereas it was 118±66.11 (95%CI 0-247.58) for >3 patients. The 1-, 2-, 3- and 5- year survival rates were 92.6%, 86.4%, 82% and 72.3% for NLR ≤3 and 80.3%, 75.6%, 65% and 56.8% for NLR >3 patients, respectively, indicating statistical significance (p=0.047).

Conclusion

In NPC, a pre-treatment NLR above three indicates an unfavorable prognosis in survival and may be a valuable prognostic biomarker. A large-scale prospective study is necessary to validate the prognostic significance of NLR in NPC patients and to determine precise cut-off values.

Zitieren

APA

Kandaz, M., Balsak, A., & Çobanoğlu, H. B. (2025). The prognostic value of neutrophil-to-lymphocyte ratio in nasopharyngeal cancer. Northwestern Medical Journal, 5(1), 16-24. https://doi.org/10.54307/nwmj.2025.77

Vancouver

Kandaz M, Balsak A, Çobanoğlu HB. The prognostic value of neutrophil-to-lymphocyte ratio in nasopharyngeal cancer. Northwestern Medical Journal. 2025;5(1):16-24. doi:10.54307/nwmj.2025.77

BibTeX
@article{Kandaz2025,
  author = {Kandaz, Mustafa and Balsak, Atalay and Çobanoğlu, Hatice Bengü},
  title = {The prognostic value of neutrophil-to-lymphocyte ratio in nasopharyngeal cancer},
  journal = {Northwestern Medical Journal},
  year = {2025},
  volume = {5},
  number = {1},
  pages = {16--24},
  doi = {10.54307/nwmj.2025.77}
}
Kostenlos starten →